GLAXO GlaxoSmithKline Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
GlaxoSmithKline Pharmaceuticals reported muted revenue growth of 2% for Q4 and FY26 due to supply chain disruptions, but achieved double-digit EBITDA and PAT growth for the full year, driven by margin expansion and efficiency gains. The company is accelerating its transition to an innovation-led portfolio, with new launches in oncology and vaccines contributing significantly to growth, and expects supply issues to normalize from Q1 FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 2.2%, net profit up 5.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,011 | 949 | 974 | 805 | 980 −3% | 1,041 +10% | 995 +2% |
| EBITDA | 322 | 292 | 333 | 251 | 336 +4% | 371 +27% | 351 +5% |
| Net profit | 252 | 230 | 263 | 205 | 257 +2% | 296 +29% | 278 +6% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
